

## DAFTAR PUSTAKA

- [1] F. Bray, M. Laversanne, E. Weiderpass, and I. Soerjomataram, “The ever-increasing importance of cancer as a leading cause of premature death worldwide,” *Cancer*, vol. 127, no. 16, pp. 3029–3030, Aug. 2021, doi: 10.1002/cncr.33587.
- [2] J. S. Brown, S. R. Amend, R. H. Austin, R. A. Gatenby, E. U. Hammarlund, and K. J. Pienta, “Updating the Definition of Cancer,” *Molecular Cancer Research*, vol. 21, no. 11, pp. 1142–1147, Nov. 2023, doi: 10.1158/1541-7786.MCR-23-0411.
- [3] “Cancer.” Accessed: May 12, 2025. [Online]. Available: [https://www.who.int/health-topics/cancer#tab=tab\\_1](https://www.who.int/health-topics/cancer#tab=tab_1)
- [4] F. Bray *et al.*, “Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” *CA Cancer J. Clin.*, vol. 74, no. 3, pp. 229–263, May 2024, doi: 10.3322/caac.21834.
- [5] “Cancer Today.” Accessed: Apr. 25, 2025. [Online]. Available: [https://gco.iarc.who.int/today/en/dataviz/bars?mode=cancer&group\\_populations=0&types=0\\_1&sort\\_by=value1&populations=900&multiple\\_populations=0&values\\_position=out&key=total](https://gco.iarc.who.int/today/en/dataviz/bars?mode=cancer&group_populations=0&types=0_1&sort_by=value1&populations=900&multiple_populations=0&values_position=out&key=total)
- [6] X. Zhao, Y. Ren, Y. Hu, N. Cui, X. Wang, and Y. Cui, “Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials,” *PLoS One*, vol. 13, no. 8, p. e0202185, Aug. 2018, doi: 10.1371/journal.pone.0202185.
- [7] J. Ke, Y. Xie, S. Huang, W. Wang, Z. Zhao, and W. Lin, “Comparison of esophageal cancer survival after neoadjuvant chemoradiotherapy plus surgery versus definitive chemoradiotherapy: A systematic review and meta-



- analysis,” *Asian J. Surg.*, vol. 47, no. 9, pp. 3827–3840, Sep. 2024, doi: 10.1016/j.asjsur.2024.02.099.
- [8] K. Wang and S. Yuan, “Current status and prospect of particle therapy for esophageal cancer,” *Precis. Radiat. Oncol.*, vol. 8, no. 2, pp. 92–98, Jun. 2024, doi: 10.1002/pro6.1232.
- [9] D. Krstić and D. Nikezić, “EXTERNAL DOSES TO HUMANS FROM <sup>137</sup>Cs IN SOIL,” *Health Phys.*, vol. 91, no. 3, pp. 249–257, Sep. 2006, doi: 10.1097/01.HP.0000214136.56619.2d.
- [10] D. Krstić and D. Nikezić, “Input files with ORNL—mathematical phantoms of the human body for MCNP-4B,” *Comput. Phys. Commun.*, vol. 176, no. 1, pp. 33–37, Jan. 2007, doi: 10.1016/j.cpc.2006.06.016.
- [11] D. Krstić and D. Nikezić, “Conversion coefficients for age-dependent ORNL phantoms from <sup>137</sup>Cs in soil as a source of external exposure,” *Nucl. Instrum. Methods Phys. Res. A*, vol. 580, no. 1, pp. 540–543, Sep. 2007, doi: 10.1016/j.nima.2007.05.225.
- [12] Y. TAKAKUSAGI *et al.*, “Dosimetric Comparison Between Carbon-ion Radiotherapy and Photon Radiotherapy for Stage I Esophageal Cancer,” *In Vivo (Brooklyn)*, vol. 35, no. 1, pp. 447–452, 2021, doi: 10.21873/invivo.12277.
- [13] M. F. Haefner *et al.*, “Intrafractional dose variation and beam configuration in carbon ion radiotherapy for esophageal cancer,” *Radiation Oncology*, vol. 11, no. 1, p. 150, Dec. 2016, doi: 10.1186/s13014-016-0727-2.
- [14] M. Suga *et al.*, “Planning strategies for robust carbon-ion scanning radiotherapy for stage I esophageal cancer: a retrospective study,” *J. Radiat. Res.*, vol. 64, no. 5, pp. 816–823, Sep. 2023, doi: 10.1093/jrr/rrad057.
- [15] E. Haettner, H. Iwase, M. Krämer, G. Kraft, and D. Schardt, “Experimental study of nuclear fragmentation of 200 and 400 MeV/u <sup>12</sup>C ions in water for



- applications in particle therapy,” *Phys. Med. Biol.*, vol. 58, no. 23, pp. 8265–8279, Dec. 2013, doi: 10.1088/0031-9155/58/23/8265.
- [16] E. Haettner, H. Iwase, and D. Schardt, “Experimental fragmentation studies with 12C therapy beams,” *Radiat. Prot. Dosimetry*, vol. 122, no. 1–4, pp. 485–487, Dec. 2006, doi: 10.1093/rpd/ncl402.
- [17] M. Puchalska, T. Tessonier, K. Parodi, and L. Sihver, “Benchmarking of PHITS for Carbon Ion Therapy,” *Int. J. Part. Ther.*, vol. 4, no. 3, pp. 48–55, Oct. 2017, doi: 10.14338/IJPT-17-00029.1.
- [18] V. Mahadevan, “Anatomy of the oesophagus,” *Surgery (Oxford)*, vol. 38, no. 11, pp. 677–682, Nov. 2020, doi: 10.1016/j.mpsur.2020.08.004.
- [19] A. Su, C. H. Parker, and J. L. Conklin, “Esophageal anatomy and physiology,” in *Clinical and Basic Neurogastroenterology and Motility*, Elsevier, 2020, pp. 79–88. doi: 10.1016/B978-0-12-813037-7.00005-4.
- [20] M. F. Ferhatoglu and T. Kivılcım, “Anatomy of Esophagus,” in *Esophageal Abnormalities*, InTech, 2017. doi: 10.5772/intechopen.69583.
- [21] E. Morgan *et al.*, “The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020,” *Gastroenterology*, vol. 163, no. 3, pp. 649–658.e2, Sep. 2022, doi: 10.1053/j.gastro.2022.05.054.
- [22] I. A. Talagala, M. Nawarathne, and C. Arambepola, “Novel risk factors for primary prevention of oesophageal carcinoma: a case-control study from Sri Lanka,” *BMC Cancer*, vol. 18, no. 1, p. 1135, Dec. 2018, doi: 10.1186/s12885-018-4975-4.
- [23] R. Obermannová *et al.*, “Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up,” *Annals of Oncology*, vol. 33, no. 10, pp. 992–1004, Oct. 2022, doi: 10.1016/j.annonc.2022.07.003.



- [24] A. Carbone, “Cancer Classification at the Crossroads,” *Cancers (Basel)*, vol. 12, no. 4, p. 980, Apr. 2020, doi: 10.3390/cancers12040980.
- [25] “AJCC Cancer Staging Manual,” *AJCC Cancer Staging Manual*, Oct. 2016, doi: 10.1007/978-3-319-40618-3.
- [26] D. Ai *et al.*, “Patterns of distant organ metastases in esophageal cancer: a population-based study,” *J. Thorac. Dis.*, vol. 9, no. 9, pp. 3023–3030, Sep. 2017, doi: 10.21037/jtd.2017.08.72.
- [27] T. W. Rice, H. Ishwaran, M. K. Ferguson, E. H. Blackstone, and P. Goldstraw, “Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer,” *Journal of Thoracic Oncology*, vol. 12, no. 1, pp. 36–42, Jan. 2017, doi: 10.1016/j.jtho.2016.10.016.
- [28] D. Jones, “ICRU Report 50—Prescribing, Recording and Reporting Photon Beam Therapy,” *Med. Phys.*, vol. 21, no. 6, pp. 833–834, Jun. 1994, doi: 10.1118/1.597396.
- [29] S. L. Morgan-Fletcher, “ICRU Report 62—Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50),” *Br. J. Radiol.*, vol. 74, no. 879, pp. 294–294, Mar. 2001, doi: 10.1259/bjr.74.879.740294.
- [30] M. Beyzadeoglu, G. Ozyigit, and C. Ebruli, “Basic radiation oncology,” *Basic Radiation Oncology*, pp. 1–575, 2010, doi: 10.1007/978-3-642-11666-7/COVER.
- [31] A. J. Wu *et al.*, “Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer,” *International Journal of Radiation Oncology\*Biography\*Physics*, vol. 92, no. 4, pp. 911–920, Jul. 2015, doi: 10.1016/J.IJROBP.2015.03.030.
- [32] IAEA, “Radiation Oncology Physics: A Handbook for Teachers and Students.” Accessed: Jan. 05, 2026. [Online]. Available: <https://www.iaea.org/publications/7086/radiation-oncology-physics>



- [33] X.-Q. Guo, R.-H. Mao, B. Liu, and H. Ge, “Study on esophageal cancer radiotherapy dosimetry and position verification for volumetric modulated arc therapy,” *Asian J. Surg.*, vol. 46, no. 1, pp. 120–125, Jan. 2023, doi: 10.1016/j.asjsur.2022.02.001.
- [34] ICRU, “ICRU Report 93—Prescribing, Recording, and Reporting Light Ion Beam Therapy,” Bethesda, MD, Dec. 2016. Accessed: Oct. 09, 2025. [Online]. Available: <https://journals.sagepub.com/toc/crua/16/1-2>
- [35] S. Bisello *et al.*, “Dose–Volume Constraints fOr oRganS At risk In Radiotherapy (CORSAIR): An ‘All-in-One’ Multicenter–Multidisciplinary Practical Summary,” *Current Oncology*, vol. 29, no. 10, pp. 7021–7050, Sep. 2022, doi: 10.3390/curroncol29100552.
- [36] R. Timmerman, “A Story of Hypofractionation and the Table on the Wall,” *International Journal of Radiation Oncology\*Biography\*Physics*, vol. 112, no. 1, pp. 4–21, Jan. 2022, doi: 10.1016/j.ijrobp.2021.09.027.
- [37] S. A. I. Al-Rawi *et al.*, “Evaluation of Conformity and Homogeneity Indices Consistency Throughout the Course of Head and Neck Cancer Treatment With and Without Using Adaptive Volumetric Modulated Arc Radiation Therapy,” *Adv. Radiat. Oncol.*, vol. 7, no. 5, p. 100905, Sep. 2022, doi: 10.1016/j.adro.2022.100905.
- [38] I. Paddick, “A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note,” *J. Neurosurg.*, vol. 93 Suppl 3, no. SUPPL. 3, pp. 219–222, 2000, doi: 10.3171/JNS.2000.93.SUPPLEMENT.
- [39] S. A. I. Al-Rawi *et al.*, “Assessment of dose gradient index variation during simultaneously integrated boost intensity-modulated radiation therapy for head and neck cancer patients,” *Precis. Radiat. Oncol.*, vol. 6, no. 3, pp. 216–224, Sep. 2022, doi: 10.1002/pro6.1166.



- [40] I. Paddick and B. Lippitz, “A simple dose gradient measurement tool to complement the conformity index,” *J. Neurosurg.*, vol. 105 Suppl, pp. 194–201, 2006, doi: 10.3171/SUP.2006.105.7.194.
- [41] G. Patel, A. Mandal, R. Shende, and A. Bharati, “Radiotherapy plan evaluation indices,” *J. Cancer Res. Ther.*, vol. 17, no. 2, pp. 455–462, Apr. 2021, doi: 10.4103/jcrt.JCRT\_417\_19.
- [42] N. Hodapp, “ICRU Report 83—prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT),” *Strahlenther. Onkol.*, vol. 188, no. 1, pp. 97–99, Jan. 2012, doi: 10.1007/S00066-011-0015-X.
- [43] H. K. Byun *et al.*, “Physical and Biological Characteristics of Particle Therapy for Oncologists,” *Cancer Res. Treat.*, vol. 53, no. 3, pp. 611–620, Jul. 2021, doi: 10.4143/crt.2021.066.
- [44] H. Iwata *et al.*, “Spot Scanning and Passive Scattering Proton Therapy: Relative Biological Effectiveness and Oxygen Enhancement Ratio in Cultured Cells,” *International Journal of Radiation Oncology\*Biology\*Physics*, vol. 95, no. 1, pp. 95–102, May 2016, doi: 10.1016/j.ijrobp.2016.01.017.
- [45] A. Michaelidesová *et al.*, “In Vitro Comparison of Passive and Active Clinical Proton Beams,” *Int. J. Mol. Sci.*, vol. 21, no. 16, p. 5650, Aug. 2020, doi: 10.3390/ijms21165650.
- [46] E. den Boer *et al.*, “Technical Note: Investigating interplay effects in pencil beam scanning proton therapy with a 4D XCAT phantom within the RayStation treatment planning system,” *Med. Phys.*, vol. 48, no. 3, pp. 1448–1455, Mar. 2021, doi: 10.1002/mp.14709.
- [47] H. Li, R. Ger, A. K. Narang, H. Chen, and J. Meyer, “Challenges and opportunities in stereotactic body proton radiotherapy of liver malignancies,” *J. Radiosurg. SBRT*, vol. 9, no. 1, pp. 83–90, 2023.



- [48] P. A. Taylor, S. F. Kry, and D. S. Followill, “Pencil Beam Algorithms Are Unsuitable for Proton Dose Calculations in Lung,” *International Journal of Radiation Oncology\*Biophysics*, vol. 99, no. 3, pp. 750–756, Nov. 2017, doi: 10.1016/j.ijrobp.2017.06.003.
- [49] Y. Zhou, Y. Li, Y. Kubota, M. Sakai, and T. Ohno, “Robust Angle Selection in Particle Therapy,” *Front. Oncol.*, vol. 11, Sep. 2021, doi: 10.3389/fonc.2021.715025.
- [50] H. Gong and B. Li, “Guidelines for Radiotherapy of Esophageal Carcinoma (2020 Edition),” *Precis. Radiat. Oncol.*, vol. 5, no. 2, pp. 54–72, Jun. 2021, doi: 10.1002/pro6.1119.
- [51] Y.-C. Zeng *et al.*, “Proton therapy posterior beam approach with pencil beam scanning for esophageal cancer,” *Strahlentherapie und Onkologie*, vol. 192, no. 12, pp. 913–921, Dec. 2016, doi: 10.1007/s00066-016-1034-4.
- [52] A. Baeyens *et al.*, “Basic Concepts of Radiation Biology,” in *Radiobiology Textbook*, Cham: Springer International Publishing, 2023, pp. 25–81. doi: 10.1007/978-3-031-18810-7\_2.
- [53] S. H. Park and J. O. Kang, “Basics of particle therapy I: physics,” *Radiat. Oncol. J.*, vol. 29, no. 3, p. 135, 2011, doi: 10.3857/roj.2011.29.3.135.
- [54] E. M. Zeman, “The Biological Basis of Radiation Oncology,” in *Clinical Radiation Oncology*, Elsevier, 2016, pp. 2-40.e5. doi: 10.1016/B978-0-323-24098-7.00001-0.
- [55] L. Rezaee, “Design of spread-out Bragg peaks in hadron therapy with oxygen ions,” *Reports of Practical Oncology & Radiotherapy*, vol. 23, no. 5, pp. 433–441, Sep. 2018, doi: 10.1016/j.rpor.2018.08.004.
- [56] W. Tinganelli and M. Durante, “Carbon ion radiobiology,” Oct. 01, 2020, *MDPI AG*. doi: 10.3390/cancers12103022.



- [57] T. Bortfeld and W. Schlegel, “An analytical approximation of depth - dose distributions for therapeutic proton beams,” *Phys. Med. Biol.*, vol. 41, no. 8, pp. 1331–1339, Aug. 1996, doi: 10.1088/0031-9155/41/8/006.
- [58] E. Haettner, H. Iwase, M. Krämer, G. Kraft, and D. Schardt, “Experimental study of nuclear fragmentation of 200 and 400 MeV/u <sup>12</sup>C ions in water for applications in particle therapy,” *Phys. Med. Biol.*, vol. 58, no. 23, pp. 8265–8279, Dec. 2013, doi: 10.1088/0031-9155/58/23/8265.
- [59] D. J. Buglewicz, K. D. Walsh, H. Hirakawa, H. Kitamura, A. Fujimori, and T. A. Kato, “Biological Effects of Monoenergetic Carbon Ions and Their Associated Secondary Particles,” *Front. Oncol.*, vol. 12, Feb. 2022, doi: 10.3389/fonc.2022.788293.
- [60] S. Endo *et al.*, “Measurement of microdosimetric spectra produced from a 290 MeV/n Spread Out Bragg Peak carbon beam,” *Radiat. Environ. Biophys.*, vol. 49, no. 3, pp. 469–475, Aug. 2010, doi: 10.1007/s00411-010-0285-1.
- [61] T. Kamada, “Twenty Years of Carbon Ion Radiation Therapy at the National Institute of Radiological Sciences: Accomplishments and Prospects,” *Int. J. Part. Ther.*, vol. 2, no. 3, pp. 459–463, Dec. 2015, doi: 10.14338/IJPT-15-00030.1.
- [62] O. Mohamad, H. Makishima, and T. Kamada, “Evolution of Carbon Ion Radiotherapy at the National Institute of Radiological Sciences in Japan,” *Cancers (Basel)*, vol. 10, no. 3, p. 66, Mar. 2018, doi: 10.3390/cancers10030066.
- [63] T. Ohno *et al.*, “Carbon Ion Radiotherapy at the Gunma University Heavy Ion Medical Center: New Facility Set-up,” *Cancers (Basel)*, vol. 3, no. 4, pp. 4046–4060, Oct. 2011, doi: 10.3390/cancers3044046.
- [64] B. L. T. Ramaekers *et al.*, “Systematic review and meta-analysis of radiotherapy in various head and neck cancers: Comparing photons, carbon-



- ions and protons,” *Cancer Treat. Rev.*, vol. 37, no. 3, pp. 185–201, May 2011, doi: 10.1016/j.ctrv.2010.08.004.
- [65] M. Li *et al.*, “Clinical Efficacy and Safety of Proton and Carbon Ion Radiotherapy for Prostate Cancer: A Systematic Review and Meta-Analysis,” *Front. Oncol.*, vol. 11, Oct. 2021, doi: 10.3389/fonc.2021.709530.
- [66] Y. Huang, Y. Dong, J. Zhao, L. Zhang, L. Kong, and J. J. Lu, “Comparison of the effects of photon, proton and carbon-ion radiation on the ectocalreticulin exposure in various tumor cell lines,” *Ann. Transl. Med.*, vol. 7, no. 20, pp. 542–542, Oct. 2019, doi: 10.21037/atm.2019.09.128.
- [67] J. Jeong, V. T. Taasti, A. Jackson, and J. O. Deasy, “The relative biological effectiveness of carbon ion radiation therapy for early stage lung cancer,” *Radiotherapy and Oncology*, vol. 153, pp. 265–271, Dec. 2020, doi: 10.1016/j.radonc.2020.09.027.
- [68] H. Feng *et al.*, “Mechanistic modelling of relative biological effectiveness of carbon ion beams and comparison with experiments,” *Phys. Med. Biol.*, vol. 69, no. 3, p. 035020, Feb. 2024, doi: 10.1088/1361-6560/ad1998.
- [69] I. A. E. AGENCY, “Relative Biological Effectiveness in Ion Beam Therapy,” *Relative Biological Effectiveness in Ion Beam Therapy*, no. 461, pp. 1–153, 2008, Accessed: Sep. 03, 2025. [Online]. Available: <https://www.iaea.org/publications/7682/relative-biological-effectiveness-in-ion-beam-therapy>
- [70] Z. Nikitaki *et al.*, “Key biological mechanisms involved in high-LET radiation therapies with a focus on DNA damage and repair,” *Expert Rev. Mol. Med.*, vol. 24, p. e15, Mar. 2022, doi: 10.1017/erm.2022.6.
- [71] D. J. Buglewicz, K. D. Walsh, H. Hirakawa, H. Kitamura, A. Fujimori, and T. A. Kato, “Biological Effects of Monoenergetic Carbon Ions and Their



- Associated Secondary Particles,” *Front. Oncol.*, vol. 12, Feb. 2022, doi: 10.3389/fonc.2022.788293.
- [72] E. Melia and J. L. Parsons, “DNA damage and repair dependencies of ionising radiation modalities,” *Biosci. Rep.*, vol. 43, no. 10, Oct. 2023, doi: 10.1042/BSR20222586.
- [73] T. Nakano *et al.*, “Formation of clustered DNA damage in vivo upon irradiation with ionizing radiation: Visualization and analysis with atomic force microscopy,” *Proceedings of the National Academy of Sciences*, vol. 119, no. 13, Mar. 2022, doi: 10.1073/pnas.2119132119.
- [74] Y. Hagiwara *et al.*, “Clustered DNA double-strand break formation and the repair pathway following heavy-ion irradiation,” *J. Radiat. Res.*, vol. 60, no. 1, pp. 69–79, Jan. 2019, doi: 10.1093/jrr/rry096.
- [75] Y. Liang, J. Wu, Z. Ding, C. Liu, and Q. Fu, “Evaluation of the Yield of DNA Double-Strand Breaks for Carbon Ions Using Monte Carlo Simulation and DNA Fragment Distribution,” *International Journal of Radiation Oncology\*Biology\*Physics*, vol. 117, no. 1, pp. 252–261, Sep. 2023, doi: 10.1016/j.ijrobp.2023.03.049.
- [76] J. Góra *et al.*, “The sensitivity of radiobiological models in carbon ion radiotherapy (CIRT) and its consequences on the clinical treatment plan: Differences between LEM and MKM models,” *J. Appl. Clin. Med. Phys.*, vol. 25, no. 7, Jul. 2024, doi: 10.1002/acm2.14321.
- [77] V. E. Bellinzona *et al.*, “Linking Microdosimetric Measurements to Biological Effectiveness in Ion Beam Therapy: A Review of Theoretical Aspects of MKM and Other Models,” *Front. Phys.*, vol. 8, Feb. 2021, doi: 10.3389/fphy.2020.578492.
- [78] A. Bertolet and A. Carabe, “Modelling Dose Effects from Space Irradiations: Combination of High-LET and Low-LET Radiations with a Modified



- Microdosimetric Kinetic Model,” ., vol. 10, no. 9, p. 161, Aug. 2020, doi: 10.3390/life10090161.
- [79] O. Mohamad *et al.*, “Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair,” *Cancers (Basel)*., vol. 9, no. 6, p. 66, Jun. 2017, doi: 10.3390/cancers9060066.
- [80] A. Wambersie *et al.*, “Isoeffective dose: a concept for biological weighting of absorbed dose in proton and heavier-ion therapies,” *Radiat. Prot. Dosimetry*, vol. 143, no. 2–4, pp. 481–486, Feb. 2011, doi: 10.1093/RPD/NCQ410.
- [81] “The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103,” *Ann. ICRP*, vol. 37, no. 2–4, pp. 1–332, 2007, doi: 10.1016/J.ICRP.2007.10.003.
- [82] T. Sato *et al.*, “Recent improvements of the particle and heavy ion transport code system – PHITS version 3.33,” *J. Nucl. Sci. Technol.*, vol. 61, no. 1, pp. 127–135, Jan. 2024, doi: 10.1080/00223131.2023.2275736.
- [83] T. Sato *et al.*, “Features of Particle and Heavy Ion Transport code System (PHITS) version 3.02,” *J. Nucl. Sci. Technol.*, vol. 55, no. 6, pp. 684–690, Jun. 2018, doi: 10.1080/00223131.2017.1419890.
- [84] R. J. McConn, C. J. Gesh, R. T. Pagh, R. A. Rucker, and R. Williams III, “Compendium of Material Composition Data for Radiation Transport Modeling,” Richland, WA (United States), Mar. 2011. doi: 10.2172/1023125.
- [85] T. Sato, K. Niita, N. Matsuda, S. Hashimoto, Y. Iwamoto, and T. Ogawa, “PHITS: Particle and Heavy Ion Transport code System, Version 3.34 User’s Manual,” 2024, *Japan Atomic Energy Agency*. [Online]. Available: <https://phits.jaea.go.jp/>



- [86] O. Iwamoto *et al.*, “Japanese evaluated nuclear data library version 5: JENDL-5,” *J. Nucl. Sci. Technol.*, vol. 60, no. 1, pp. 1–60, Jan. 2023, doi: 10.1080/00223131.2022.2141903.
- [87] T. Ogawa *et al.*, “Overview of PHITS Ver.3.34 with particular focus on track-structure calculation,” *EPJ Nuclear Sciences & Technologies*, vol. 10, p. 13, Nov. 2024, doi: 10.1051/epjn/2024012.
- [88] Y. Matsuya *et al.*, “Development of a chemical code applicable to ions based on the PHITS code for efficient and visual radiolysis simulations,” *Physical Chemistry Chemical Physics*, vol. 27, no. 14, pp. 6887–6898, 2025, doi: 10.1039/D4CP04216F.
- [89] *ICRP Publication 110 Adult Reference Computational Phantoms*. Elsevier. [Online]. Available: <https://www.icrp.org/publication.asp?id=icrp%20publication%20110>
- [90] “ICRP Publication 145—Adult Mesh-type Reference Computational Phantoms”, doi: 10.1177/ANIB\_49\_3.
- [91] F. D. Sowby *et al.*, “ICRP Publication 44—Protection of the Patient in Radiation Therapy”, doi: 10.1177/ANIB\_15\_2.
- [92] R. R. Dufera, A. Osman, I. Nnamani, O. Tolu-Akinnawo, and D. Smoot, “The Rare Case of Esophageal Cancer Presenting With Hematemesis in a 29-Year-Old Adult,” *Cureus*, Jun. 2023, doi: 10.7759/cureus.39881.
- [93] A. Boyer *et al.*, “AAPM Report No. 072—Basic Applications of Multileaf Collimators,” 2001, doi: 10.37206/71.
- [94] T. Kamada, “Overview of the heavy-ion medical accelerator in Chiba (HIMAC) Practices,” *Carbon-Ion Radiotherapy: Principles, Practices, and Treatment Planning*, pp. 3–22, Jan. 2014, doi: 10.1007/978-4-431-54457-9\_3.



- [95] R. Budiman, H. Sutanto, R. Tursinah, and P. Triadyaksa, “Dose Distribution of Pencil Beam Proton Therapy using Geant4 Simulation for Breast Cancer Treatment,” *Journal of Physics and Its Applications*, vol. 7, no. 2, pp. 43–47, May 2025, doi: 10.14710/JPA.V7I2.25067.
- [96] T. Isozaki *et al.*, “Outcomes of definitive carbon-ion radiotherapy for cT1bN0M0 esophageal squamous cell carcinoma,” *Esophagus*, vol. 21, no. 4, pp. 523–529, Oct. 2024, doi: 10.1007/S10388-024-01067-7.

